Tampa, FL Clinical Trials Report — July 2026

Tampa participants should act promptly: 49 recruiting trials are expected to close within the next 90 days, including 4 that accept healthy volunteers. The largest group of closing studies involves atopic dermatitis, with 3 trials, followed by aggression, breast cancer, cancer, and ovarian cancer, with 2 each.

Tampa currently has 1,034 recruiting clinical trials across 427 research facilities. Thirteen trials opened in July, down from 15 in May and 15 in June. Because enrollment may end early when study targets are reached, people who match a closing-soon condition should contact local research teams now.

Closing opportunities for patients and healthy volunteers

The conditions most represented among Tampa trials approaching their projected closing dates are:

• Atopic dermatitis (3 trials)
• Aggression (2 trials)
• Breast cancer (2 trials)
• Cancer more generally (2 trials)
• Ovarian cancer (2 trials)
• Chemotherapy-induced neuropathic pain (1 trial)
• Asthma (1 trial)
• Alzheimer disease (1 trial)
• Cardiovascular diseases (1 trial)
• Amputees (1 trial)

Four of the closing-soon studies accept healthy volunteers. Tampa has 55 healthy-volunteer trials recruiting overall, but eligibility can differ substantially by study. Screening may involve age requirements, medical history, medication restrictions, laboratory testing, or multiple visits. Healthy adults who are interested should ask each site whether enrollment is still open and whether the study has a compensated or unpaid participation structure.

New July studies include major late-stage research

July’s new-trial mix includes 8 drug studies, 3 biological studies, 2 device studies, and studies categorized as other, behavioral, or genetic. Industry sponsors account for 8 new trials, while other sponsors account for 5. The month’s leading sponsor is H. Lee Moffitt Cancer Center and Research Institute, with 3 new studies, followed by AstraZeneca with 2.

Several Phase 2 and Phase 3 studies stand out for participants seeking research from established sponsors or local academic investigators:

• NCT07735637, the Phase 3 DURGA-6 study sponsored by AstraZeneca, compares consolidation treatment with AZD0120 against autologous stem-cell transplantation in transplant-eligible participants with newly diagnosed multiple myeloma. The planned enrollment is 750 participants.
• NCT07734415 is a Phase 2 long-term safety and efficacy study of IMG-007 for people with moderate-to-severe atopic dermatitis. Inmagene LLC plans to enroll 400 participants.
• NCT07702578 is a Phase 3 study sponsored by TScan Therapeutics evaluating genetically randomized, T-cell receptor-engineered donor T cells after allogeneic stem-cell transplantation. The study plans to enroll 310 participants.
• NCT07723963 is a Phase 2/Phase 3 Jazz Pharmaceuticals study evaluating JZP926 capsules for juvenile myoclonic epilepsy, with planned enrollment of 260 participants.
• NCT07724340 is a Phase 2 Antag Therapeutics study of AT673 given with semaglutide in adults with type 2 diabetes and overweight or obesity. It plans to enroll 150 participants.
• NCT07728123, sponsored by Westat, is the Screen2Prevent study examining broad-scale HIV screening approaches in emergency departments. The study lists planned enrollment of 84,000 participants.

Other new Tampa categories include breast cancer, acute myeloid leukemia, ankle-foot orthosis research, cardiomyopathy, Friedreich ataxia, HIV infections, and infertility. One July study accepts healthy volunteers. Five new trials include children, one is female-only, none are male-only, and 11 include older adults.

Moffitt is Tampa’s largest research hub

Moffitt Cancer Center is the city’s dominant clinical research location, with 289 recruiting trials. The University of South Florida follows with 106, while Tampa General Hospital has 58. These sites give Tampa residents access to especially strong oncology and academic research programs, along with studies in neurology, cardiology, dermatology, metabolic disease, and other specialties.

• Moffitt Cancer Center (289 trials)
• University of South Florida (106 trials)
• Tampa General Hospital (58 trials)
• Saint Joseph’s Hospital/Children’s Hospital-Tampa (38 trials)
• Research Site (34 trials)
• Moffitt Cancer Center - McKinley Campus (28 trials)
• Moffitt Cancer Center-International Plaza (24 trials)
• Moffit Cancer Center (10 trials)
• St. Joseph’s Children’s Hospital (8 trials)
• Neurocrine Clinical Site (8 trials)
• K2 Medical Research - Tampa (8 trials)
• USF Health (7 trials)

People seeking cancer studies should begin with Moffitt and its affiliated campuses. USF, USF Health, and Tampa General provide broader academic and hospital-based options, while K2 Medical Research and Neurocrine Clinical Site may be useful starting points for selected outpatient or specialty studies.

Florida alternatives and the outlook for volunteers

If a suitable Tampa study is unavailable, participants may also search other Florida cities. Miami has 15 nearby recruiting trials, followed by Orlando with 7. Coral Gables, Fort Myers, Jacksonville, and Hollywood each have 5, while Miami Lakes has 4 and Fort Lauderdale has 3.

Tampa’s monthly number of new trials has declined from 17 in February to 22 in March, 20 in April, 18 in May, 15 in June, and 13 in July; the dataset lists 5 for August. With late-stage drug studies opening alongside a substantial group of trials nearing closure, July is a good time to verify eligibility, compare travel requirements, and contact sites before summer enrollment windows narrow further.